Axsome Therapeutics (AXSM) Net Cash Flow (2015 - 2026)

Axsome Therapeutics has disclosed Net Cash Flow across 12 years of filings, most recently posting -$17.8 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$17.8 million, down 23.43% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.2 million (up 113.74% YoY), and the FY2025 annual result was $7.6 million, up 110.7% from the prior year.
• Net Cash Flow came in at -$17.8 million for Q1 2026 at Axsome Therapeutics, down from -$2.3 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $190.6 million in Q2 2023 to a low of -$54.8 million in Q1 2024.
• The 5-year median for Net Cash Flow is -$11.3 million (2022), against an average of $12.9 million.
• Across the five-year window, Net Cash Flow surged 2687.71% in 2023 and sank 219.88% in 2024, its largest moves.
• Axsome Therapeutics' Net Cash Flow stood at -$26.7 million in 2022, then fell by 13.84% to -$30.4 million in 2023, then surged by 60.53% to -$12.0 million in 2024, then soared by 80.49% to -$2.3 million in 2025, then plunged by 662.16% to -$17.8 million in 2026.
• The last three Net Cash Flow figures came in at -$17.8 million (Q1 2026), -$2.3 million (Q4 2025), and $22.3 million (Q3 2025), per Business Quant data.